| CTRI Number |
CTRI/2025/02/080659 [Registered on: 17/02/2025] Trial Registered Prospectively |
| Last Modified On: |
04/07/2025 |
| Post Graduate Thesis |
No |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug Other (Specify) [Bumsuit Baby Cream, Lotion, Massage Oil and Shampoo] |
| Study Design |
Single Arm Study |
|
Public Title of Study
|
Testing the Safety of Bumsuit Baby Products for Skin Irritation and Allergies in Healthy Children |
|
Scientific Title of Study
|
A Non Randomized, Open Label, Single Center Study to Evaluate the Irritation and Sensitization Potential of Baby Products in Healthy Volunteer Children using Primary Irritation Test.
|
| Trial Acronym |
Nil |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| CTSRS/2427 Version No. 1.0 Dated 11/Dec/2024 |
Protocol Number |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Uday Kumar S |
| Designation |
Principal Investigator |
| Affiliation |
Samahitha Research Solutions |
| Address |
Currex Hospital, No.55-56, Seegehalli Main Road, Bhoo Samartha Layout
Bangalore KARNATAKA 560059 India |
| Phone |
06364898825 |
| Fax |
|
| Email |
pi.clinicaltrial@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Ms Sathyavathi L M |
| Designation |
HOD-Clinical Operations |
| Affiliation |
Samahitha Research Solutions |
| Address |
Clinical Research Unit No.1204, Ashva, 2nd Floor, 26th Main,
Jayanagar 9th Block, Bangalore
Bangalore
Bangalore KARNATAKA 560069 India |
| Phone |
9739001749 |
| Fax |
|
| Email |
satyalm@samahitha.com |
|
Details of Contact Person Public Query
|
| Name |
Ms Arpita Malgi |
| Designation |
Team Lead - Clinical Operations |
| Affiliation |
Samahitha Research Solutions |
| Address |
Clinical Research Unit No.1204, Ashva, 2nd Floor, 26th Main,
Jayanagar 9th Block, Bangalore
Bangalore
Bangalore KARNATAKA 560069 India |
| Phone |
06364898825 |
| Fax |
|
| Email |
arpita@samahitha.com |
|
|
Source of Monetary or Material Support
|
| Kamson Healthcare Pvt. Ltd.
Sy.No:546,AA1,AA2, Nandigam ( Village & Mandal)
Rangareddy Dist., Telangana,India -509228 |
|
|
Primary Sponsor
|
| Name |
Kamson Healthcare Pvt. Ltd. |
| Address |
Sy.No:546,AA1,AA2, Nandigam ( Village & Mandal)
Rangareddy Dist., Telangana,India -509228 |
| Type of Sponsor |
Pharmaceutical industry-Indian |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Uday Kumar S |
Currex Hospital |
Currex Hospital
No.55-56, Seegehalli Main Road, Bhoo Samartha Layout,
Seegehalli, KS Halli, Bengaluru Bangalore KARNATAKA |
06364898825
pi.clinicaltrial@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Pranav Diabetes Center Ethics Committee |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Healthy Human Volunteers |
To Evaluate the Irritation and Sensitization Potential of Bumsuit Baby Products in Healthy Volunteer Children using Primary Irritation Test. |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Bumsuit Baby Cream, Bumsuit Baby Lotion, Bumsuit Baby Massage Oil, and Bumsuit Baby Shampoo |
The products will be applied in a patch chamber (0.04 ml) to evaluate skin irritancy and allergic sensitization. The duration of treatment will be 24 hours, with a one-hour window, for a period of 14 days (with an additional one-day window). |
| Comparator Agent |
NA |
NA |
|
|
Inclusion Criteria
|
| Age From |
5.00 Year(s) |
| Age To |
18.00 Year(s) |
| Gender |
Both |
| Details |
1. Healthy volunteers aged 5 to 18 years.
2. Subjects with no clinically significant dermatological conditions e.g., eczema, psoriasis.
3. Subjects whose guardians/parents have provided Informed Consent.
4. Willing to adhere to study restrictions no use of other skincare products in the test area.
|
|
| ExclusionCriteria |
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
On-site computer system |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
| Measurement of local skin reactions such as erythema (redness), edema (swelling), dryness, or scaling at the application site after 24 hours. These will be scored using a standard irritation scoring scale. |
Day 0, Day 1, Day 2, Day 3 and Day 7 |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| Observation of any signs of allergic sensitization, such as delayed erythema, papules, or vesicles, occurring post-24-hour patch removal and in subsequent follow-ups. Sensitization will be scored and categorized based on the intensity of reactions. |
Day 0, Day 1, Day 2, Day 3 and Day 7 |
|
|
Target Sample Size
|
Total Sample Size="24" Sample Size from India="24"
Final Enrollment numbers achieved (Total)= "24"
Final Enrollment numbers achieved (India)="24" |
|
Phase of Trial
|
Phase 3 |
|
Date of First Enrollment (India)
|
18/02/2025 |
| Date of Study Completion (India) |
28/02/2025 |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Date Missing |
|
Estimated Duration of Trial
|
Years="0" Months="0" Days="7" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Completed |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
Brief Summary
Modification(s)
|
Background and Introduction The early years are recognized as crucial for children’s healthy development, and proper skincare is considered essential for their long-term well-being. During childhood and adolescence, the skin undergoes several changes, highlighting the need for skincare products to be both safe and effective. Baby products, commonly used to moisturize and protect the skin are to be carefully evaluated to ensure they do not cause irritation or sensitization, particularly since children’s skin is more delicate than that of adults. Participants with varied skin types were included to determine whether the product is safe for use in children and adolescents. The aim of the study was to provide essential data to confirm the product’s safety, enabling its confident recommendation by parents, caregivers, and healthcare professionals. Purpose of the Study The purpose of the study was to evaluate the irritation and sensitization potential of baby products when applied to the skin of healthy children and adolescents aged 5 to 18 years. A primary irritation test was conducted under controlled occlusive conditions to assess the dermatological safety of the products and confirm their suitability for use on sensitive skin. The findings contributed to confirming that the products met safety standards and could be confidently recommended for pediatric use. Results The study was conducted over a 7- day period for each participant.A total of 24 healthy children (12 males and 12 females) aged 5 to 18 years were enrolled who successfully completed the study. The average age of participants was 12.9 years. The study assessed four baby care products: Bumsuit Baby Cream, Lotion, Massage Oil, and Shampoo. Primary Endpoint: No signs of erythema (redness), edema (swelling), dryness, or peeling were observed in any subject during the study. All participants consistently recorded a score of zero on the Draize scale, confirming that the products were non-irritating and well-tolerated. Secondary Endpoint: None of the participants reported sensations of burning, itching, tingling, or other signs of allergic skin reactions. There were no instances of acute or delayed sensitization observed throughout the study period. Safety Outcomes: No adverse events (AEs) or serious adverse events (SAEs) were reported. Compliance was 100%, and no protocol deviations or subject withdrawals occurred. |